ORTHOPEDIATRICS CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ORTHOPEDIATRICS CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $98.05M | Mar 3, 2022 |
| FY2021 | Dec 31, 2020 | $71.08M | Mar 3, 2022 |
| FY2021 | Dec 31, 2019 | $72.55M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $57.56M | Mar 11, 2021 |
| FY2017 | Dec 31, 2017 | $11.68M | Mar 15, 2018 |
| FY2017 | Sep 30, 2017 | $12.38M | Mar 15, 2018 |
| FY2017 | Jun 30, 2017 | $11.80M | Mar 15, 2018 |
| FY2017 | Mar 31, 2017 | $9.76M | Mar 15, 2018 |
| FY2017 | Dec 31, 2016 | $9.42M | Mar 15, 2018 |
| FY2017 | Sep 30, 2016 | $10.14M | Mar 15, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $236.35M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $204.73M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $148.73M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $122.29M | Mar 5, 2025 |
| FY2021 | Dec 31, 2021 | $24.81M | Mar 3, 2022 |
| FY2021 | Sep 30, 2021 | $25.08M | Mar 3, 2022 |
| FY2021 | Jun 30, 2021 | $26.70M | Mar 3, 2022 |
| FY2021 | Mar 31, 2021 | $21.46M | Mar 3, 2022 |
| FY2021 | Dec 31, 2020 | $18.92M | Mar 3, 2022 |
| FY2021 | Sep 30, 2020 | $22.21M | Mar 3, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $172.66M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $148.60M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $111.25M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $90.66M | Mar 5, 2025 |
| FY2021 | Dec 31, 2021 | $18.08M | Mar 3, 2022 |
| FY2021 | Sep 30, 2021 | $18.55M | Mar 3, 2022 |
| FY2021 | Jun 30, 2021 | $20.44M | Mar 3, 2022 |
| FY2021 | Mar 31, 2021 | $16.33M | Mar 3, 2022 |
| FY2021 | Dec 31, 2020 | $15.12M | Mar 3, 2022 |
| FY2021 | Sep 30, 2020 | $17.64M | Mar 3, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($39.65M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($37.82M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($20.97M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $1.26M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | ($16.26M) | Mar 8, 2024 |
| FY2020 | Dec 31, 2020 | ($14.01M) | Mar 11, 2021 |
| FY2020 | Sep 30, 2020 | ($4.54M) | Mar 11, 2021 |
| FY2020 | Jun 30, 2020 | ($9.45M) | Mar 11, 2021 |
| FY2020 | Mar 31, 2020 | ($4.95M) | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | ($5.43M) | Mar 11, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($39.24M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($35.01M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($26.75M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | ($25.40M) | Mar 5, 2025 |
| FY2021 | Dec 31, 2021 | ($5.56M) | Mar 3, 2022 |
| FY2021 | Sep 30, 2021 | ($3.64M) | Mar 3, 2022 |
| FY2021 | Jun 30, 2021 | ($2.85M) | Mar 3, 2022 |
| FY2021 | Mar 31, 2021 | ($5.97M) | Mar 3, 2022 |
| FY2021 | Dec 31, 2020 | ($12.74M) | Mar 3, 2022 |
| FY2021 | Sep 30, 2020 | ($2.50M) | Mar 3, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.10M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $11.03M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $10.90M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $8.45M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $5.54M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $5.27M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $5.75M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $4.73M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $3.42M | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | $2.22M | Mar 7, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.85M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($27.05M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($27.05M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | ($21.77M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | ($13.06M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | ($18.53M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($17.77M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | ($15.58M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | ($7.22M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | ($1.12M) | Mar 7, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.11M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $14.26M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $16.88M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $10.03M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $8.10M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $10.50M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $11.82M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $5.25M | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $5.21M | Mar 5, 2020 |
| FY2018 | Dec 31, 2016 | $4.35M | Mar 7, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $508.63M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $473.21M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $438.75M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $427.73M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $304.27M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $320.41M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $182.15M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $112.11M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $82.30M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $30.68M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $162.03M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $118.64M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $61.72M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $49.08M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $78.91M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $85.64M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $39.79M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $30.37M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $34.81M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $24.68M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $346.60M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $354.57M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $377.03M | Mar 4, 2026 |
| FY2025 | Dec 31, 2022 | $378.65M | Mar 4, 2026 |
| FY2024 | Dec 31, 2021 | $225.37M | Mar 5, 2025 |
| FY2023 | Dec 31, 2020 | $234.77M | Mar 8, 2024 |
| FY2022 | Dec 31, 2019 | $142.36M | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $81.73M | Mar 3, 2022 |
| FY2020 | Dec 31, 2017 | $47.50M | Mar 11, 2021 |
| FY2019 | Dec 31, 2016 | ($65.31M) | Mar 5, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $109.27M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $93.84M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $83.70M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $86.82M | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | $72.35M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $70.51M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $13.77M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $0 | Mar 11, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($275.21M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($235.56M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($197.74M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | ($176.77M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($178.03M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($161.77M) | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | ($128.82M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($115.09M) | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | ($103.07M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($78.13M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.56M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $43.82M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $31.06M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $8.99M | Mar 8, 2024 |
| FY2021 | Dec 31, 2021 | $7.64M | Mar 3, 2022 |
| FY2021 | Dec 31, 2020 | $28.76M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $70.78M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $60.69M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $42.58M | Mar 7, 2019 |
| FY2018 | Dec 31, 2016 | $1.61M | Mar 7, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.01M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $77.48M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $11.06M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $907.0K | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $1.04M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.18M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $26.19M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $21.27M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | $25.45M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $17.54M | Mar 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 5, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 3, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 3, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 3, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 3, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 3, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 3, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 5, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 3, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 3, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 3, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 3, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 3, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Mar 3, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.09M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 24.22M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 23.38M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 22.88M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 19.68M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 19.56M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | 16.72M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 14.54M | Mar 5, 2020 |
| FY2018 | Dec 31, 2017 | 12.62M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 2.42M | Mar 15, 2018 |